Eye on Education
 

Allergan News

Print this Article | Send to Colleague

Allergan, an AbbVie Company, Submits New Drug Application for Investigational AGN-190584 for the Treatment of Presbyopia

- If approved, this is expected to be the first eye drop to treat presbyopia
- Presbyopia is a common, progressive condition that reduces the aging eye's ability to focus on near objects and affects nearly half of the adult U.S. population
- AGN-190584 met primary endpoint, reaching statistical significance in improvement in near vision without a loss of distance vision in two pivotal Phase 3 studies involving 750 patients

Allergan, an AbbVie (NYSE: ABBV) company, announces that it has submitted a New Drug Application to the U.S. Food and Drug Administration for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. The FDA is expected to act on the NDA by the end of 2021.

Approximately 128 million adults in the U.S. experience presbyopia, a common and progressive eye condition that reduces the eye's ability to focus on near objects and usually impacts people after age 40. Yet, compared to other eye-related conditions, there is a much lower awareness of presbyopia by name.

"Presbyopia is a significant source of frustration for most adults over age 40 who find current treatments inconvenient or invasive," said Tom Hudson, MD, senior vice president, R&D, chief scientific officer, AbbVie. "If approved, AGN-190584 is expected to be the first eye drop to treat presbyopia, providing a novel option to those affected in the U.S."

The NDA is based primarily on data from two Phase 3 GEMINI 1 and GEMINI 2 clinical studies, which evaluated the efficacy, safety and tolerability of AGN-190584 (pilocarpine 1.25%). A total of 750 patients were randomized in a one-to-one ratio of vehicle (placebo) to AGN-190584. In both studies, AGN-190584 met the primary endpoint reaching statistical significance in improvement in near vision in mesopic (in low light) conditions without a loss of distance vision vs. the vehicle. There were no treatment emergent serious adverse events observed in any AGN-190584 treated participants. The most common treatment emergent non-serious adverse events occurring at a frequency of ≥5% in AGN-190584 treated participants were headache and conjunctival hyperemia.

The Phase 3 GEMINI 1 and GEMINI 2 top-line results were previously announced in October 2020, and additional details of these studies will be presented at upcoming medical meetings this year.

 

Back to Eye on Education

Share on Facebook Share on Twitter Share on LinkedIn